Advertisement

Prognostic impact of postoperative infection in patients with pancreatic cancer: A multicenter cohort study

Published:October 25, 2022DOI:https://doi.org/10.1016/j.surg.2022.09.002

      Abstract

      Background

      Postoperative infection after pancreatectomy in patients with pancreatic cancer often leads to poor prognosis. The aim of this study was to determine the prognostic effect of postoperative infection in patients with pancreatic cancer.

      Methods

      A multicenter cohort study was performed using a common database of patients with pancreatic cancer who underwent curative pancreatic resections between April 2013 and March 2015 at 15 high-volume centers in Japan. The rate of postoperative infection was determined, and patient demographic characteristics, clinicopathologic factors, and prognostic factors for overall survival were analyzed.

      Results

      Of the 462 eligible patients who underwent curative pancreatectomy, postoperative infection occurred in 141 patients (31%), including 114 surgical site infections (25%), 50 remote infections (11%), and 23 combined infections (5%). Risk factors for postoperative infection included high body mass index, nondiabetes, and longer operation time. In the survival analysis, patients with postoperative infection had significantly worse overall survival than patients without postoperative infection. The median survival times were 21.9 and 33.0 months (P = .023), respectively, for patients with and without postoperative infection. According to the multivariate analysis for overall survival, lack of adjuvant therapy (P = .002), but not postoperative infection (P = .829), predicted poor prognosis. The multivariate analysis revealed that postoperative infection (P < .001) was an independent risk factor for lack of adjuvant therapy.

      Conclusion

      Postoperative infection in patients with pancreatic cancer may indirectly worsen the prognosis by preventing timely adjuvant therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Rahib L.
        • Smith B.D.
        • Aizenberg R.
        • Rosenzweig A.B.
        • Fleshman J.M.
        • Matrisian L.M.
        Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
        Cancer Res. 2014; 74: 2913-2921
        • Hackert T.
        • Buchler M.W.
        • Werner J.
        Current state of surgical management of pancreatic cancer.
        Cancers (Basel). 2011; 3: 1253-1273
        • Jang J.Y.
        • Han Y.
        • Lee H.
        • et al.
        Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial.
        Ann Surg. 2018; 268: 215-222
        • Kondo N.
        • Uemura K.
        • Sudo T.
        • et al.
        A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
        Eur J Cancer. 2021; 159: 215-223
        • Uesaka K.
        • Boku N.
        • Fukutomi A.
        • et al.
        Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
        Lancet. 2016; 388: 248-257
        • Conroy T.
        • Hammel P.
        • Hebbar M.
        • et al.
        FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.
        N Engl J Med. 2018; 379: 2395-2406
        • Merkow R.P.
        • Bilimoria K.Y.
        • Tomlinson J.S.
        • et al.
        Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.
        Ann Surg. 2014; 260: 372-377
        • Wei T.
        • Zhang X.F.
        • Bagante F.
        • et al.
        Postoperative infectious complications worsen long-term survival after curative-intent resection for hepatocellular carcinoma.
        Ann Surg Oncol. 2022; 29: 315-324
        • Yang T.
        • Liu K.
        • Liu C.F.
        • et al.
        Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma.
        Br J Surg. 2019; 106: 1228-1236
        • Kano K.
        • Aoyama T.
        • Yoshikawa T.
        • et al.
        The negative survival impact of infectious complications after surgery is canceled out by the response of neoadjuvant chemotherapy in patients with esophageal cancer.
        Ann Surg Oncol. 2018; 25: 2034-2043
        • Li S.S.
        • Udelsman B.V.
        • Parikh A.
        • et al.
        Impact of postoperative complication and completion of multimodality therapy on survival in patients undergoing gastrectomy for advanced gastric cancer.
        J Am Coll Surg. 2020; 230: 912-924
        • Maruyama H.
        • Kusachi S.
        • Makino H.
        • Kanno H.
        • Yoshida H.
        • Niitsuma T.
        Postoperative infection after colorectal surgery: subanalysis of data from the 2015 Japan Postoperative Infectious Complications Survey.
        J Nippon Med Sch. 2020; 87: 204-210
        • Kulu Y.
        • Tarantio I.
        • Warschkow R.
        • et al.
        Anastomotic leakage is associated with impaired overall and disease-free survival after curative rectal cancer resection: a propensity score analysis.
        Ann Surg Oncol. 2015; 22: 2059-2067
        • Aoyama T.
        • Oba K.
        • Honda M.
        • et al.
        Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials.
        Cancer Med. 2017; 6: 1573-1580
        • Garner J.S.
        • Jarvis W.R.
        • Emori T.G.
        • Horan T.C.
        • Hughes J.M.
        CDC definitions for nosocomial infections, 1988.
        Am J Infect Control. 1988; 16: 128-140
        • Bassi C.
        • Marchegiani G.
        • Dervenis C.
        • et al.
        The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after.
        Surgery. 2017; 161: 584-591
        • Korol E.
        • Johnston K.
        • Waser N.
        • et al.
        A systematic review of risk factors associated with surgical site infections among surgical patients.
        PLoS One. 2013; 8e83743
        • Fukuda H.
        Patient-related risk factors for surgical site infection following eight types of gastrointestinal surgery.
        J Hosp Infect. 2016; 93 (3473–54)
        • Callery M.P.
        • Pratt W.B.
        • Kent T.S.
        • Chaikof E.L.
        • Vollmer Jr., C.M.
        A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy.
        J Am Coll Surg. 2013; 216: 1-14
        • Nishimuta H.
        • Kusachi S.
        • Watanabe M.
        • et al.
        Impact of postoperative remote infection on length of stay and medical costs in hospitals in Japan.
        Surg Today. 2021; 51: 212-218
        • Murakami Y.
        • Uemura K.
        • Sudo T.
        • et al.
        Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.
        Cancer Chemother Pharmacol. 2013; 71: 419-429